چكيده به لاتين
This dissertation aims to kill ovarian cancer cells purposefully with a new hybrid magnetic nanocarrier. In this study, preparation and characterization of a nanoscale drug nanocarrier, made of spherical and magnetic iron nanoparticles, gold nanoparticles, Docetaxel, as a toxic anticancer agent, 3-chloropropyl trimethoxy silane, as a hydrophobic agent, and a ligand for the binding of antibodies, Sortilin monoclonal antibody (2D8-E3), a human IgG1 monoclonal antibody, was well performed and validated by a variety of assay methods. The antitumor activity of this new and advanced hybrid nanocarrier, as well as drug binding on the caov4 cell line (ATCC HTB76) has been carefully investigated. Sortilin monoclonal antibody is also well expressed on this hybrid nanocarrier. In the following, the anti-cancer activity of the nanocarriers has been investigated by in-vitro test. Using the new DXL@Fe3O4-PVA/Au-SORT nanosuspension, illustrates effectiveness in drug delivery as well as excellent control of Docetaxel release by placing the drug into a polyvinyl alcohol polymer network. By presence of gold nanoparticles on ironoxide nanoparticles, using Localized Surface Plasmon Resonance (LSPR) activity of gold nanoparticles, swelling of polyvinyl alcohol would happen and cytotoxic drug releases. This excellent targeting is achieved using the monoclonal antibody Sortilin. Methyltetrazole(MTT) assay has performed in the caov-4 cell line to quantitatively evaluate the toxicity and killing potential of cells, and the selective function of DXL@Fe3O4-PVA/Au-SORT nanoparticles. Flowcytometry results confirm that 63±2. 2.1% cell binding (33.5÷52.5×100) occurred after binding of SORT antibody to nanoparticles. Due to the acidity of both caov-4 cells and infrared radiation, the release of Docetaxel has increased dramatically. Thus, it can be claimed that a very good synergistic effect has occurred. Because, the therapeutic effect of Plasmonic photo thermal therapy (PPTT) stimulates gold nanoparticles, thereby, raising the temperature. This upsurge in temperature causes the polyvinyl alcohol polymer network to swell and release more drugs. According to the results, only 25.3±3.7% of the caov-4 cells treated with DXL@Fe3O4-PVA/Au-SORT (50μg/ml) survived. With all abovementioned reasons taken into account, various analyzes have shown that according to this strategy, Docetaxel reaches caov-4 cancer cells targetedly, so that a significant reduction in the side effects of chemotherapy would happen.
